1. Home
  2. RPD vs IOVA Comparison

RPD vs IOVA Comparison

Compare RPD & IOVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Rapid7 Inc.

RPD

Rapid7 Inc.

HOLD

Current Price

$15.40

Market Cap

1.0B

Sector

Technology

ML Signal

HOLD

Logo Iovance Biotherapeutics Inc.

IOVA

Iovance Biotherapeutics Inc.

HOLD

Current Price

$2.85

Market Cap

968.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RPD
IOVA
Founded
2000
2007
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.0B
968.6M
IPO Year
2015
N/A

Fundamental Metrics

Financial Performance
Metric
RPD
IOVA
Price
$15.40
$2.85
Analyst Decision
Hold
Buy
Analyst Count
21
12
Target Price
$24.00
$10.45
AVG Volume (30 Days)
1.1M
11.3M
Earning Date
02-11-2026
11-06-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.35
N/A
Revenue
$858,667,000.00
$250,425,000.00
Revenue This Year
$2.62
$60.71
Revenue Next Year
$1.49
$59.52
P/E Ratio
$44.24
N/A
Revenue Growth
3.08
175.62
52 Week Low
$13.21
$1.64
52 Week High
$41.38
$8.15

Technical Indicators

Market Signals
Indicator
RPD
IOVA
Relative Strength Index (RSI) 43.64 69.24
Support Level $15.06 $2.08
Resistance Level $15.90 $2.60
Average True Range (ATR) 0.46 0.17
MACD -0.03 0.07
Stochastic Oscillator 15.93 87.36

Price Performance

Historical Comparison
RPD
IOVA

About RPD Rapid7 Inc.

Founded in 2000, Rapid7 is a cybersecurity company that began providing vulnerability management solutions. It has, however, expanded its portfolio to provide extended detection and response; security information and event management; cloud security, threat intelligence, and application security; and security orchestration, automation, and response. The Boston-based company went public in 2015.

About IOVA Iovance Biotherapeutics Inc.

Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.

Share on Social Networks: